HCQ+IS (HCQ: 0.2 g twice daily for /min/1.73 m2; 0.1 g twice or thrice daily for eGFR 30-60 ml/min/1.73 m2; 0.1 g once daily for eGFR 15-30 ml/min/1.73 m2)
Conventional IS
vs.
34.6% vs. 38.5%
2.35 (1.47, 2.98) vs. 2.35 (1.54, 2.98)
2 months −40.17% (−48.71, −20.88) vs. −13.4% (−61.66,42.97) 4 months −33.62% (−49.15, −13.95) vs. −30.43% (−64.4, 0.00) 6 months −39.81% (−66.26, −12.37) vs. −31.99% (−67.08, −9.14)
HCQ+RAASi (HCQ: 0.2 g twice daily for /min/1.73 m2; 0.1 g thrice daily for eGFR 45-60 ml/min/1.73 m2; 0.1 g twice daily for eGFR 30-45 ml/min/1.73 m2; 0.1 g once daily for /min/1.73 m2)
RAASi
vs.
49.4% vs. 35.3%
1.55 (1.16, 2.23) vs. 1.56 (0.98, 2.37)
12 months −38.24% (−54.45, −14.26) vs. −52.05% (−81.87, −27.86) 24 months −35.69% (−70.33, −2.36) vs. −74.12% (−82.51, −58.30)
7
HCQ: hydroxychloroquine; eGFR: estimated glomerular filtration rate; E/C: experimental group/control group; RAASi: renin-angiotensin-aldosterone system inhibition; IS: immunosuppressive agent.